Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
4,633,811
-
Share change
-
-832,745
-
Total reported value
-
$928,378
-
Put/Call ratio
-
31%
-
Price per share
-
$0.20
-
Number of holders
-
51
-
Value change
-
-$3,135,364
-
Number of buys
-
24
-
Number of sells
-
22
Institutional Holders of BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) as of Q3 2023
As of 30 Sep 2023,
BRAINSTORM CELL THERAPEUTICS - COM NEW (BCLI) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,633,811 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock Inc., LIBERTY WEALTH MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, GTS SECURITIES LLC, MILLENNIUM MANAGEMENT LLC, ABNER HERRMAN & BROCK LLC, RAYMOND JAMES & ASSOCIATES, and SABBY MANAGEMENT, LLC.
This page lists
51
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.